Abstract
Apparent differences in the effectiveness of adjuvant therapies according to age, has led to controversy concerning the optimum treatment for women with breast cancer above and below 50 years of age. The data upon which this controversy is based and the possible reasons why chemotherapy appears more active in young women, whilst endocrine therapy appears more active in older women, is examined.
| Original language | English |
|---|---|
| Pages (from-to) | 231-7 |
| Number of pages | 7 |
| Journal | Hormone Research |
| Volume | 32 Suppl 1 |
| Publication status | Published - 1989 |
Keywords
- Adult
- Age Factors
- Antineoplastic Agents
- Breast Neoplasms
- Drug Evaluation
- Female
- Humans
- Middle Aged
- Tamoxifen
- Journal Article
